Clinical Trial Economics in the AI Era

About this white paper

The economics of clinical development are changing

For years, sponsors have paid for software systems, outsourced services, and internal teams to connect the work between them. That model faces a new question: when AI can help detect issues, coordinate workflows, and prepare actions, what should organizations actually buy? This executive whitepaper examines the shift toward governed clinical execution: work performed with trial context, defined controls, human oversight, and an auditable record. It explores what that shift could mean for software pricing, CRO delivery models, sponsor operating costs, and the clinical teams responsible for outcomes.

Key takeaways

What you'll learn

• Why the traditional split between software access and service delivery is under pressure.
• How AI changes the cost structure of clinical software, including usage, validation, monitoring, and human review.
• Why study context, workflow control, governance, and accountable action may become more valuable than standalone features.
• How software vendors, CROs, and sponsors may need to rethink pricing, capacity, and ownership of clinical work.
• Which questions executives should ask before investing in an AI enabled clinical operating model.